A review of artificial pancreas technologies with an emphasis on bi‐hormonal therapy
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Since the discovery of insulin, great progress has been made to improve the accuracy and safety of automated insulin delivery systems to help patients with type 1 diabetes achieve their treatment goals without causing hypoglycaemia. In recent years, bioengineering technology has greatly advanced diabetes management, with the development of blood glucose meters, continuous glucose monitors, insulin pumps and control systems for automatic delivery of one or more hormones. New insulin analogues have improved subcutaneous absorption characteristics, but do not completely eliminate the risk of hypoglycaemia. Insulin effect is counteracted by glucagon in non‐diabetic individuals, while glucagon secretion in those with type 1 diabetes is impaired. The use of glucagon in the artificial pancreas is therefore a logical and feasible option for preventing and treating hypoglycaemia. However, commercially available glucagon is not stable in aqueous solution for long periods, forming potentially cytotoxic fibrils that aggregate quickly. Therefore, a more stable formulation of glucagon is needed for long‐term use and storage in a bi‐hormonal pump. In addition, a model of glucagon action in type 1 diabetes is lacking, further limiting the inclusion of glucagon into systems employing model‐assisted control. As a result, although several investigators have been working to help develop bi‐hormonal systems for patients with type 1 diabetes, most continue to utilize single hormone systems employing only insulin. This article seeks to focus on the attributes of glucagon and its use in bi‐hormonal systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
(2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420603 · Cited by 1,534
In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes
Kovatchev, B. P., Breton, M., Dalla Man, C., & Cobelli, C. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300106 · Cited by 760
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541
A Bihormonal Closed-Loop Artificial Pancreas for Type 1 Diabetes
El-Khatib, F. H., Russell, S. J., Nathan, D. M., Sutherlin, R. G., & Damiano, E. R. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000619 · Cited by 403
Hypoglycemia, functional brain failure, and brain death.
Cryer, P. E. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31669 · Cited by 363
Closed-loop insulin delivery from bench to clinical practice
Hovorka, R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.32 · Cited by 342
Effectiveness of Continuous Glucose Monitoring in a Clinical Care Environment
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2010) · Diabetes Care · doi:10.2337/dc09-1502 · Cited by 313
Continuous glucose monitoring systems for type 1 diabetes mellitus
Langendam, M., Luijf, Y. M., Hooft, L., DeVries, J. H., Mudde, A. H., & Scholten, R. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008101.pub2 · Cited by 262
Hovorka, R., Kumareswaran, K., Harris, J., Allen, J. M., Elleri, D., Xing, D., Kollman, C., Nodale, M., Murphy, H. R., Dunger, D. B., et al. (2011) · BMJ · doi:10.1136/bmj.d1855 · Cited by 244 · cited 1×
“initially implemented a Model Predictive Control (MPC)-based adaptive control algorithm to treat children and adolescents with T1DM and concluded that overnight closed-loop insulin delivery improved glycaemic control and reduced glucose excursion and nocturnal hypoglycaemia [20,38].”
Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes
Castle, J. R., Engle, J. M., Youssef, J. E., Massoud, R. G., Yuen, K. C. J., Kagan, R., & Ward, W. K. (2010) · Diabetes Care · doi:10.2337/dc09-2254 · Cited by 232
Self-citationClarke, W. L., Anderson, S., Breton, M., Patek, S., Kashmer, L., & Kovatchev, B. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300506 · Cited by 185
Insulin Pump Therapy With Automated Insulin Suspension in Response to Hypoglycemia
Choudhary, P., Shin, J., Wang, Y., Evans, M. L., Hammond, P. J., Kerr, D., Shaw, J. A. M., Pickup, J. C., & Amiel, S. A. (2011) · Diabetes Care · doi:10.2337/dc10-2411 · Cited by 175
Prevention of Nocturnal Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension
Buckingham, B., Chase, H. P., Dassau, E., Cobry, E., Clinton, P., Gage, V., Caswell, K., Wilkinson, J., Cameron, F., Lee, H., et al. (2010) · Diabetes Care · doi:10.2337/dc09-2303 · Cited by 169
Haidar, A., Legault, L., Dallaire, M., Alkhateeb, A., Coriati, A., Messier, V., Cheng, P., Millette, M., Boulet, B., & Rabasa-Lhoret, R. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.121265 · Cited by 167
Garg, S., Brazg, R. L., Bailey, T. S., Buckingham, B. A., Slover, R. H., Klonoff, D. C., Shin, J., Welsh, J. B., & Kaufman, F. R. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0292 · Cited by 138 · cited 2×
“Early studies of LGS found a lower duration and severity of hypoglycaemia without leading to significant hyperglycaemia [52].”
El-Khatib, F. H., Jiang, J., & Damiano, E. R. (2007) · Journal of Diabetes Science and Technology · doi:10.1177/193229680700100208 · Cited by 99
Amperometric Glucose Sensors: Sources of Error and Potential Benefit of Redundancy
Castle, J. R., & Ward, W. K. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400127 · Cited by 95 · cited 1×
“Improvements in sensor accuracy [30] and in pump technology have also greatly improved the efficacy of artificial pancreas systems.”
Self-citationYoussef, J. E., Castle, J. R., Branigan, D. L., Massoud, R. G., Breen, M. E., Jacobs, P. G., Bequette, B. W., & Ward, W. K. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500602 · Cited by 42 · cited 1×
“This algorithm, termed the adaptive-proportional derivative (APD) system, correctly detected the reduced sensitivity, increased insulin delivery accordingly and minimized the resulting rise in glucose [61].”
Self-citationWard, W. K., Castle, J. R., & Youssef, J. E. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500608 · Cited by 36
Self-citation
Cited by
Weisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
Coming of age: the artificial pancreas for type 1 diabetes
Thabit, H., & Hovorka, R. (2016) · Diabetologia · doi:10.1007/s00125-016-4022-4 · Cited by 223
The artificial pancreas: current status and future prospects in the management of diabetes
Peyser, T., Dassau, E., Breton, M., & Skyler, J. S. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12431 · Cited by 169
Zeng, B., Gao, L., Yang, Q., Jia, H., & Sun, F. (2023) · Diabetes Care · doi:10.2337/dc23-0504 · Cited by 100
Herrero, P., Georgiou, P., Oliver, N., Reddy, M., Johnston, D., & Toumazou, C. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700416 · Cited by 55
Metadata
- Authors
- Bakhtiani, P. A., Zhao, L. M., El Youssef, J., Castle, J. R., & Ward, W. K.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2013-04-21
- Volume
- 15
- Issue
- 12
- Pages
- 1065-1070
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2003594741
- Cited by
- 65
- References
- 20
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.